Liotta, D; Holt, J; Natchus, M; Galinski, M; Baille, M; Miller, E

Hot flashes associated with altered endocrine function are a significant challenge for women, in particular for those undergoing chemotherapeutic treatment for certain diseases. Que Oncology has in-licensed and is developing a small molecular therapeutic that may be useful for ameliorating the effects of such treatments by reducing these symptoms. A Phase I clinical trial found positive results for using the compound to treat hot flashes in women receiving anti-estrogen therapy for breast cancer. Next, Que Oncology will conduct a dose defining Phase 2 study in the patient population.